October 16, 2008
Cheetah Medical Announces European Launch of New Reliant(R) 2.0 System for Advanced Noninvasive Hemodynamic Monitoring
Cheetah Medical today announced the European launch of its new Reliant(R) 2.0 System. In addition to core hemodynamic parameters including Cardiac Output (CO), Cardiac Index (CI) and Stroke Volume (SV), the Reliant 2.0 adds new parameters to provide a comprehensive suite of information for hemodynamic monitoring - all without the need for invasive modalities with the associated potential costs and risks. The new parameters include Noninvasive Blood Pressure (NIBP)(1), Total Peripheral Resistance (TPR),(1) Stroke Volume Variation (SVV), Cardiac Power (CP), and Change in Thoracic Fluid Content (TFCd). The Reliant 2.0 System will be showcased at the American Society of Anesthesiology Annual Meeting in Orlando, Florida through October 21st, with live, interactive demonstrations held at the Cheetah Medical exhibit #2646.
"Accurate continuous hemodynamic monitoring to support real-time decisions on fluids and drugs is today a critical component of diagnosis and treatment in many acute conditions, thanks to substantial improvement in patient outcomes," says Yoav Avidor MD, CEO of Cheetah Medical. "We believe that the Reliant monitor provides the accurate, noninvasive monitoring solution physicians need in order to implement cutting-edge clinical protocols across a wide array of patients in a cost-effective fashion."
About the Reliant System and Noninvasive Hemodynamic Monitoring
The Reliant hemodynamic monitoring platform is powered by Cheetah's unique, patented BIOREACTANCE(R) Technology, which has been used effectively in over 2,000 patients in various clinical settings including medical and surgical intensive care, perioperative care, emergency medicine, heart failure, hemodialysis and exercise testing.
Advanced hemodynamic monitoring including cardiac output monitoring is useful to guide fluid resuscitation and drug titration in a number of conditions which affect millions of patients, including high-risk perioperative, sepsis, trauma, heart failure, pulmonary hypertension and hemodialysis. When used in a real-time, continuous mode in the context of specific treatment algorithms, advanced hemodynamic and cardiac output monitoring has been shown to reduce mortality, morbidity and length of hospital stay in numerous studies. However, leading cardiac output modalities are invasive, costly and add potential risks. Consequently, advanced hemodynamic monitoring with cardiac output is not utilized in millions of cases per year where it could be of value. Cheetah Medical believes that the Reliant system offers the noninvasive, accurate, comprehensive and cost-effective solution physicians need in order to implement these important approaches.
About Cheetah Medical
Cheetah Medical delivers accurate noninvasive cardiac output (CO), thoracic fluid content (TFC) and other vital hemodynamic monitoring parameters to provide continuous, clinically actionable data for fluid and drug optimization in acute care settings, including intensive care, emergency and perioperative patient management. The Reliant System uses Cheetah Medical's proprietary BIOREACTANCE(R) technology which has validated performance accuracy and faster directional changes compared to invasive CO measurement methods and less potential risks. Cheetah Medical has offices in Tel Aviv, Israel and has recently relocated its United States headquarters to Portland, Oregon. For more information about Cheetah Medical, visit our website at www.cheetah-medical.com.
(1)While the Reliant monitor is FDA cleared, NIBP, TPR and related new features are under FDA review and are not currently available for sale within the United States.